Ulla is a seasoned professional in cancer biology with over 15 years of experience in oncology drug development from discovery to Phase I. As a profound scientist she has contributed key discoveries that enables clinical development. Ulla has held leadership roles at Bayer and Anji Pharma, leading high-performing global project teams in virtual and real-world settings. Ulla currently serves also as the CEO of Trueline Therapeutics, leveraging her ability to bridge science and business with a passion for advancing oncology therapies.

Ulla received her B.S. in Biological Sciences from the University of Konstanz, her M.Sc. in Cancer Biology from the University of Sussex and her PhD in Biology from the Max Delbrück Center for Molecular Medicine, Berlin Buch and the Humboldt University Berlin.

Doug has over 20 years of experience in protein science and engineering for the discovery of both biologic and low molecular weight therapeutics. He established a protein science and structural biology group at the Broad Institute before he joined Novartis as project team leader in a biologics group. Doug has made key discoveries to progress multiple partnered programs currently nearing clinical trials. In his time leading groups in and collaborating across pharma, start-up, non-profit, and academic environments of the drug discovery ecosystem, Doug has experience spanning metabolic, cardiovascular, oncology, and infectious disease areas.

Doug has B.S. degrees in Chemistry and Cell & Molecular Biology from the University of Michigan. He received a Ph.D. in Biochemistry and Structural Biology from the Scripps Research Institute and was a postdoctoral fellow at Yale University.

Virendar has over 20 years of drug discovery experience with expertise in biochemistry, biophysics, and structure-based drug design. He directed a therapeutics development group at the Broad Institute and led multiple cross-functional project teams aimed at bringing transformative medicines to patients with cardiovascular, metabolic, oncologic, or infectious disease. Additionally, Virendar was a leader of and key contributor to drug discovery programs that entered clinical development at Novartis and Millennium Pharmaceuticals.

Virendar received his B.A. in Biology and M.A. in Physiology from Boston University, and his Ph.D in Nutritional Biochemistry from Tufts University.

Matthias brings more than 20 years of academic and industry experience in oncology and GI diseases at Bayer and at Boehringer Ingelheim. He held global senior positions in early drug development with a strong focus on biomarkers, translational medicine and clinical pharmacology. Matthias has led several programs into Phase 1 and to proof of concept and was a member of global portfolio steering committees. He has authored more than 130 scientific publications and book chapters and is a member of several academic societies like AACR and EASL.

Matthias received his M.D. from Friedrich-Alexander-University Erlangen-Nuremberg, Germany, and is a faculty member and adjunct professor of experimental medicine at Charité University Medicine Berlin, Germany.

Chloe brings expertise in stakeholder and alliance management with a focus on early-stage life science companies. In her most recent role at Viva BioInnovator, Chloe led investment diligence and strategy development for 50+ portfolio companies. In her previous roles in the Florida state senate and the Institute for Nonprofit Innovation and Excellence, she focused on project management, industry review, and advocacy.

Chloe received her M.A. in Asian Studies with a concentration in Economics and a B.S. in International Affairs and Economics from Florida State University. Chloe also studied at Fudan University, Shanghai, and Koc University, Istanbul.